Skip to main content
padlock icon - secure page this page is secure

Open Access Operational aspects of bedaquiline implementation in Swaziland: report from the field

Download Article:
(PDF 362.3 kb)
Bedaquiline (BDQ) has been recommended by the World Health Organization for the treatment of multi-drug-resistant tuberculosis (MDR-TB) since 2013, but experience using the drug in high-burden, lower-income countries is limited and case studies are needed. Swaziland started using BDQ under national TB programme conditions in 2015 in four pilot sites. As of 1 December 2016, 93 patients had been initiated on BDQ, i.e., 19% of MDR-TB patients treated in the country. Swaziland has developed a systematic and efficient model for BDQ introduction in collaboration with several partners. This model is also being used to introduce other innovations and can serve as an example for other countries facing similar challenges.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: BDQ; MDR-TB; Swaziland

Document Type: Research Article

Affiliations: 1: National Tuberculosis Control Programme, Manzini, Swaziland 2: Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA 3: Médecins Sans Frontières (MSF), Shiselweni, Swaziland 4: MSF, Manzini, Swaziland 5: Management Sciences for Health, Mbabane, Swaziland 6: National Tuberculosis Referral Hospital, Manzini, Swaziland 7: World Health Organization, Mbabane, Swaziland

Publication date: September 21, 2017

More about this publication?
  • Public Health Action (PHA), The Union's quarterly open access on-line journal, provides a platform for its mission 'Health solutions for the poor'. PHA addresses the need for show-casing operational research that addresses issues in health systems and services. It publishes high-quality scientific research that provides new knowledge to improve access, equity, quality and efficiency of health systems and services.

  • Editorial Board
  • Information for Authors
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more